Drug resistance

LUNGevity and Hamoui Foundations Issue RFA for Research Into RET-positive Lung Cancer

Retrieved on: 
Thursday, January 25, 2024

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to announce its second partnership with the Hamoui Foundation to issue an RFA (Request for Application) for the Hamoui Foundation/LUNGevity Clinical Research Award for RET-positive Lung Cancer.
  • The Hamoui Foundation/LUNGevity RET-positive Award aims to address this gap by funding research to improve outcomes for patients with RET-positive lung cancer.
  • "In 2021, when we announced our first partnership with Hamoui Foundation, it was clear that without philanthropic funding in this area, the research would not happen," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research.
  • "We awarded $1 million in research grants to gain insights into understanding non-genomic mechanisms of drug resistance in RET-positive lung cancer, leveraging existing FDA-approved drugs to treat RET-positive lung cancer, and studying the structural changes to altered RET proteins.

LUNGevity Issues RFA Focused on Immunotherapy Resistance in Lung Cancer

Retrieved on: 
Thursday, January 25, 2024

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to issue an RFA (Request for Application) for the Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to issue an RFA (Request for Application) for the Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy.
  • This award, supported by the Brown Family from Atlanta, GA, aims to study how metastatic non-small cell lung cancer becomes resistant to immunotherapy and how we can avoid or overcome this drug resistance.
  • Immunotherapy has revolutionized our approach to treating lung cancer.
  • "The Brown/LUNGevity Award for Immunotherapy Resistance aims to directly address this need by supporting impactful, patient-focused research to help us address resistance to immunotherapy."

LUNGevity and Rising Tide Foundation Partner to Issue RFA for $1.5M to Improve Outcomes for People Living with Lung Cancer

Retrieved on: 
Thursday, January 25, 2024

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is honored to announce its partnership with the Rising Tide Foundation to issue an RFA (Request for Application) for the Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is honored to announce its partnership with the Rising Tide Foundation to issue an RFA (Request for Application) for the Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance.
  • Approximately 45%-50% of lung adenocarcinomas are known to harbor oncogenic drivers that have been successfully targeted by treatments.
  • While many patients benefit from these targeted therapies, the tumors will eventually develop drug resistance and begin to grow again.
  • "Understanding these shared mechanisms of drug resistance is a major need in the lung cancer community," said Upal Basu Roy, PhD, MPH, executive director of LUNGevity Research.

Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer

Retrieved on: 
Tuesday, January 16, 2024

The trial aims to enroll 60 patients who have developed clear resistance to osimertinib, as well as those who have shown partial sensitivity to the drug.

Key Points: 
  • The trial aims to enroll 60 patients who have developed clear resistance to osimertinib, as well as those who have shown partial sensitivity to the drug.
  • Lung cancer patients with epidermal growth factor receptor (EGFR) mutations typically receive EGFR-antagonists like osimertinib as a first line treatment.
  • While effective initially, patients on osimertinib therapy eventually develop resistance.
  • ENV105 is a first-in-class biologic developed to enhance the sensitivity of EGFR-driven lung cancer patients to EGFR-antagonists.

Lung Cancer Research Foundation Announces 2024 Requests for Proposals

Retrieved on: 
Thursday, January 11, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Today, the Lung Cancer Research Foundation (LCRF) announced that its 2024 funding mechanisms are now open for submission.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Today, the Lung Cancer Research Foundation (LCRF) announced that its 2024 funding mechanisms are now open for submission.
  • "Each year, LCRF funds innovative new ideas to understand treatment resistance, tackle disparities, increase the diversity of the lung cancer research workforce and support science that seeks solutions to lung cancer's many complexities.
  • LCRF's Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer is focused on identifying, characterizing, and developing approaches that will detect lung cancer at the earliest stages.
  • LCRF's Minority Career Development Award (CDA) for Lung Cancer is a two-year career development award intended to support early-stage scientists from underrepresented groups working in lung cancer in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers

Retrieved on: 
Friday, January 5, 2024

Turbine, a leading biological simulation company building a platform for interpreting human biology in silico, today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.

Key Points: 
  • Turbine, a leading biological simulation company building a platform for interpreting human biology in silico, today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.
  • Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers.
  • The collaboration will focus on understanding resistance mechanisms resulting from altered protein-protein interactions, which could enable more personalized treatment regimens based on each patient’s molecular profile.
  • Simulations were used to identify potential mechanisms underlying the synergy between combinations of cancer treatments, revealing biomarkers of response and resistance that could be translated into clinical practice.

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

Retrieved on: 
Tuesday, December 19, 2023

TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.

Key Points: 
  • TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.
  • In Japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, (MHLW).
  • This application is based on the results of a multicenter, open-label, single-arm clinical phase II trial (Study 201) in Japan and China conducted by Eisai.
  • Study 201 enrolled patients with unresectable biliary tract cancer with FGFR2 gene fusion previously treated with gemcitabine-based combination chemotherapy.

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors

Retrieved on: 
Thursday, December 21, 2023

London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announces the appointments of Dr Bo Rode Hansen PhD, MBA and Dr Marco Gottardis, PhD as Non-Executive Directors of its Board.

Key Points: 
  • London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announces the appointments of Dr Bo Rode Hansen PhD, MBA and Dr Marco Gottardis, PhD as Non-Executive Directors of its Board.
  • He currently advises Novo Seeds (Novo Holdings), a life science investment company and consults for different life science, biotech, and investment companies.
  • He previously served as the CEO and President of Scandion Oncology A/S, a Danish cancer drug resistance company.
  • Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of the Board, I’m delighted to welcome both Bo and Marco onto our Board of Directors as key hires for LIfT’s next phase as we move into license deals.